At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results